Interestingly, Kitano’s study found 146 different HER2 antibodies in 14 patients, although no tumor regression was observed, while Curigliano’s study evidenced an overall clinical benefit rate of 30%, although the median time to disease progression was modest (2.8 to 3.4 months). Here, ERBB2 is linked to neoplasm.